


## WE CLAIM

1. A compound of Formula I:



in which:

$n$  is chosen from 0, 1 and 2;  $m$  is chosen from 1, 2 and 3;

$R_1$  is chosen from  $C_{6-10}$ aryl and  $C_{5-10}$ heteroaryl; wherein any aryl or heteroaryl of  $R_1$  is optionally substituted by a radical chosen from  $C_{6-10}$ aryl $C_{0-4}$ alkyl,  $C_{5-6}$ heteroaryl $C_{0-4}$ alkyl,  $C_{3-8}$ cycloalkyl $C_{0-4}$ alkyl,  $C_{3-8}$ heterocycloalkyl $C_{0-4}$ alkyl or  $C_{1-10}$ alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of  $R_1$  can be optionally substituted by 1 to 5 radicals chosen from halo,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy; and any alkyl group of  $R_1$  can optionally have a methylene replaced by an atom or group chosen from  $-S-$ ,  $-S(O)-$ ,  $-S(O)_2-$ ,  $-NR_7-$  and  $-O-$ ; wherein  $R_7$  is chosen from hydrogen and  $C_{1-6}$ alkyl;

$R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently chosen from hydrogen, halo, hydroxy,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy;

$A$  is chosen from  $-X_1C(O)OR_7$ ,  $-X_1OP(O)(OR_7)_2$ ,  $-X_1P(O)(OR_7)_2$ ,  $-X_1P(O)OR_7$ ,  $-X_1S(O)_2OR_7$ ,  $-X_1P(O)(R_7)OR_7$  and 1*H*-tetrazol-5-yl; wherein  $X_1$  is chosen from a bond,  $C_{1-3}$ alkylene and  $C_{2-3}$ alkenylene and  $R_7$  is chosen from hydrogen and  $C_{1-6}$ alkyl;

$B$  is  $CR_8R_9$ ; wherein  $R_8$  and  $R_9$  are independently chosen from hydrogen, hydroxy,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy;

$E$  is chosen from  $CR_8$  or  $N$ ; wherein  $R_8$  is chosen from hydrogen, hydroxy,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy; or  $B$  is  $CR_9$  and  $E$  is carbon and  $B$  and  $E$  are connected via a double bond;


X is a bond or is chosen from  $-X_1OX_2-$ ,  $-X_1NR_7X_2-$ ,  $-X_1C(O)NR_7X_2-$ ,  $-X_1NR_7C(O)X_2-$ ,  $-X_1S(O)X_2-$ ,  $-X_1S(O)_2X_2-$ ,  $-X_1SX_2-$ , C<sub>4-6</sub>heteroarylene and  $-X_1ON=C(R_7)X_2-$ ; wherein X<sub>1</sub> and X<sub>2</sub> are independently chosen from a bond, C<sub>1-3</sub>alkylene and C<sub>2-3</sub>alkenylene; R<sub>7</sub> is chosen from hydrogen and C<sub>1-6</sub>alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and C<sub>1-6</sub>alkyl;

Y is chosen from C<sub>6-10</sub>aryl and C<sub>5-10</sub>heteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydroxy, nitro, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkoxy, halo-substituted C<sub>1-10</sub>alkyl and halo-substituted C<sub>1-10</sub>alkoxy; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

2. The compound of claim 1 in which R<sub>1</sub> is chosen from phenyl, naphthyl and thiophenyl optionally substituted by C<sub>6-10</sub>arylC<sub>0-4</sub>alkyl, C<sub>5-6</sub>heteroarylC<sub>0-4</sub>alkyl, C<sub>3-8</sub>cycloalkylC<sub>0-4</sub>alkyl, C<sub>3-8</sub>heterocycloalkylC<sub>0-4</sub>alkyl or C<sub>1-10</sub>alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R<sub>1</sub> can be optionally substituted by 1 to 5 radicals chosen from halo, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkoxy, halo-substituted-C<sub>1-10</sub>alkyl and halo-substituted-C<sub>1-10</sub>alkoxy; and any alkyl group of R<sub>1</sub> can optionally have a methylene replaced by an atom or group chosen from  $-S-$ ,  $-S(O)-$ ,  $-S(O)_2-$ ,  $-NR_7-$  and  $-O-$ ; wherein R<sub>7</sub> is hydrogen or C<sub>1-6</sub>alkyl.


3. The compound of claim 1 in which A is chosen from  $-X_1C(O)OR_7$  and 1*H*-tetrazol-5-yl; wherein X<sub>1</sub> is chosen from a bond, C<sub>1-3</sub>alkylene and C<sub>2-3</sub>alkenylene and R<sub>7</sub> is chosen from hydrogen and C<sub>1-6</sub>alkyl.

4. The compound of claim 1 in which X is chosen from:




wherein the left and right asterisks of X indicate the point of attachment between  $R_1$  and Y of Formula I, respectively;  $R_7$  is chosen from hydrogen and  $C_{1-6}$ alkyl;  $v$  and  $w$  are independently 0, 1, 2 or 3.

5. The compound of claim 1 in which Y is chosen from:



wherein R<sub>7</sub> is hydrogen or C<sub>1-6</sub>alkyl; and the left and right asterisks of Y indicate the point of attachment between X and E of Formula I, respectively.

6. The compound of claim 2 in which R<sub>1</sub> is chosen from:




wherein the asterisk is the point of attachment of R<sub>1</sub> with X; R<sub>10</sub> is C<sub>6-10</sub>arylC<sub>0-4</sub>alkyl, C<sub>5-6</sub>heteroarylC<sub>0-4</sub>alkyl, C<sub>3-8</sub>cycloalkylC<sub>0-4</sub>alkyl, C<sub>3-8</sub>heterocycloalkylC<sub>0-4</sub>alkyl or C<sub>1-10</sub>alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R<sub>10</sub> can be optionally substituted by 1 to 3 radicals chosen from halo, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkoxy, halo-substituted-C<sub>1-10</sub>alkyl and halo-substituted-C<sub>1-10</sub>alkoxy; and any alkyl group of R<sub>10</sub> can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -S(O)<sub>2</sub>-, -NR<sub>7</sub>- and -O-; wherein R<sub>7</sub> is hydrogen or C<sub>1-6</sub>alkyl; and R<sub>11</sub> is selected from halo, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkoxy, halo-substituted-C<sub>1-10</sub>alkyl and halo-substituted-C<sub>1-10</sub>alkoxy.

7. The compound of claim 2 selected from: 3-{4-[6-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-pyridin-3-yl]-piperazin-1-yl}-propionic acid; 3-{4-[6-(4-

Cyclohexyl-3-trifluoromethyl-phenoxy-methyl)-pyridin-3-yl]-piperazin-1-yl}-propionic acid; 3-{4-[6-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-pyridazin-3-yl]-piperazin-1-yl}-propionic acid; 3-{4-[2-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-pyrimidin-5-yl]-piperazin-1-yl}-propionic acid; 3-{4-Hydroxy-4-[2-(2-trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5-yl]-piperidin-1-yl}-propionic acid; 3-{4-[2-(2-Trifluoromethyl-biphenyl-4-yl)-benzo[b]thiophen-5-yl]-3,6-dihydro-2H-pyridin-1-yl}-propionic acid; 3-(3-{4-[3-(2-Trifluoromethyl-biphenyl-4-yl)-[1,2,4]oxadiazol-5-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(3-{3-[5-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(3-{3-[5-(2-Trifluoromethyl-biphenyl-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(3-{4-[3-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(4-{4-[5-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-piperidin-1-yl)-propionic acid; 3-(3-{4-[5-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(3-{4-[5-(2-Trifluoromethyl-biphenyl-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-pyrrolidin-1-yl)-propionic acid; 3-(4-{4-[5-(2-Trifluoromethyl-biphenyl-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-piperidin-1-yl)-propionic acid; 3-(3-{4-[5-(4-Cyclohexyl-3-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-azetidin-1-yl)-propionic acid; 3-(3-{4-[5-(2-Trifluoromethyl-biphenyl-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-azetidin-1-yl)-propionic acid; 3-(4-{4-[5-(3-Trifluoromethyl-phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-piperidin-1-yl)-propionic acid; 3-{4-[6-(2-Trifluoromethyl-biphenyl-4-yloxy-methyl)-pyridin-3-yl]-piperazin-1-yl}-propionic acid; and 3-{4-[4-(2-Trifluoromethyl-biphenyl-4-ylsulfanylmethyl)-phenyl]-piperidin-1-yl}-propionic acid.

8. The compound of claim 2 of Formula Ia:



in which:

E is selected from N and CH;

m and n are independently selected from 0 and 1;

v and w are independently selected from 0 and 1;

R<sub>10</sub> is selected from cyclohexyl, piperidinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl; wherein any cyclohexyl, piperidinyl, tetrahydro-thiopyran-4-yl, phenyl, phenoxy and phenylsulfanyl of R<sub>10</sub> can be optionally substituted by 1 to 3 radicals independently selected from methyl and isopropyl;

R<sub>11</sub> is selected from methyl, trifluoromethyl and ethyl; and

R<sub>12</sub> is selected from hydrogen, ethyl and methoxy.

9. The compound of claim 8 selected from: 3-{4-[4-(4-Cyclohexyl-3-methyl-phenoxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Piperidin-1-yl-3-trifluoromethyl-phenoxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-(4-{4-[3-Methyl-4-(tetrahydro-thiopyran-4-yl)-phenoxy)methyl]-phenyl}-piperidin-1-yl)-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-2-ethyl-phenyl]-piperazin-1-yl}-propionic acid; 3-{4-[4-(2-Methyl-biphenyl-4-yloxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(2-Trifluoromethyl-biphenyl-4-yloxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-phenoxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(3'-Methyl-2-trifluoromethyl-biphenyl-4-yloxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-phenoxy)methyl]-phenyl]-pyrrolidin-1-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-ethyl-phenoxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyl-4-yloxy)methyl]-phenyl]-pyrrolidin-1-yl}-propionic acid; 3-(4-{4-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-trifluoromethyl-phenoxy)methyl]-phenyl}-piperidin-1-yl)-propionic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-phenyl]-azetidin-1-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyl-4-yloxy)methyl]-phenyl]-azetidin-1-yl}-propionic acid; 3-{4-[2-Ethyl-4-(2-trifluoromethyl-biphenyl-4-yloxy)methyl]-phenyl]-piperidin-1-yl}-propionic acid; 3-{3-[4-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-phenyl]-pyrrolidin-1-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-

benzyloxy)-2-ethyl-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4'-Methyl-2-trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Phenoxy-3-trifluoromethyl-phenoxy-methyl)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Cyclohexyl-3-trifluoromethyl-phenoxy-methyl)-2-methoxy-phenyl]-piperazin-1-yl}-propionic acid; 3-{4-[4-(2-Trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-piperidin-1-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-propionic acid; 3-{3-[4-(2-Trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-azetidin-1-yl}-propionic acid; 3-{4-[4-(4-Isobutyl-3-trifluoromethyl-benzyloxy)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(4-Phenylsulfanyl-3-trifluoromethyl-phenoxy-methyl)-phenyl]-piperidin-1-yl}-propionic acid; 1-(1H-Tetrazol-5-ylmethyl)-4-[4-(2-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-piperidine; 1-[2-(1H-Tetrazol-5-yl)-ethyl]-4-[4-(2-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-piperidine; 3-{4-[4-(2,4'-Dimethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(2,4'-Dimethyl-biphenyl-4-ylmethoxy)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(2-Ethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-propionic acid; 3-{4-[4-(2-Ethyl-3'-methyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-propionic acid; (2-{4-[4-(2-Trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-ethyl)-phosphonic acid; 2-{4-[4-(2-Trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-ethanesulfonic acid; and Phosphoric acid mono-(2-{4-[4-(2-trifluoromethyl-biphenyl-4-yloxymethyl)-phenyl]-piperidin-1-yl}-ethyl) ester.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.


11. A method for treating a disease in an animal in which alteration of EDG/S1P receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

12. A method for preventing or treating disorders or diseases mediated by lymphocytes, for preventing or treating acute or chronic transplant rejection or T-cell

mediated inflammatory or autoimmune diseases, for inhibiting or controlling deregulated angiogenesis, or for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject comprising administering to the subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

13. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which alteration of EDG/S1P receptor mediated signal transduction contributes to the pathology and/or symptomology of the disease.

14. A process for preparing a compound of Formula I:



in which:

$n$  is chosen from 0, 1 and 2;  $m$  is chosen from 1, 2 and 3;

$R_1$  is chosen from  $C_{6-10}$ aryl and  $C_{5-10}$ heteroaryl; wherein any aryl or heteroaryl of  $R_1$  is optionally substituted by a radical chosen from  $C_{6-10}$ aryl $C_{0-4}$ alkyl,  $C_{5-6}$ heteroaryl $C_{0-4}$ alkyl,  $C_{3-8}$ cycloalkyl $C_{0-4}$ alkyl,  $C_{3-8}$ heterocycloalkyl $C_{0-4}$ alkyl or  $C_{1-10}$ alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of  $R_1$  can be optionally substituted by 1 to 5 radicals chosen from halo,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy; and any alkyl group of  $R_1$  can optionally have a methylene replaced by an atom or group chosen from  $-S-$ ,  $-S(O)-$ ,  $-S(O)_2-$ ,  $-NR_7-$  and  $-O-$ ; wherein  $R_7$  is chosen from hydrogen and  $C_{1-6}$ alkyl;

$R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently chosen from hydrogen, halo, hydroxy,  $C_{1-10}$ alkyl,  $C_{1-10}$ alkoxy, halo-substituted- $C_{1-10}$ alkyl and halo-substituted- $C_{1-10}$ alkoxy;

$A$  is chosen from  $-X_1C(O)OR_7$ ,  $-X_1OP(O)(OR_7)_2$ ,  $-X_1P(O)(OR_7)_2$ ,  $-X_1P(O)OR_7$ ,  $-X_1S(O)_2OR_7$ ,  $-X_1P(O)(R_7)OR_7$  and 1*H*-tetrazol-5-yl; wherein  $X_1$  is chosen from a bond,  $C_{1-3}$ alkylene and  $C_{2-3}$ alkenylene and  $R_7$  is chosen from hydrogen and  $C_{1-6}$ alkyl;




B is  $\text{CR}_8\text{R}_9$ ; wherein  $\text{R}_8$  and  $\text{R}_9$  are independently chosen from hydrogen, hydroxy,  $\text{C}_{1-10}$ alkyl,  $\text{C}_{1-10}$ alkoxy, halo-substituted- $\text{C}_{1-10}$ alkyl and halo-substituted- $\text{C}_{1-10}$ alkoxy;

E is chosen from  $\text{CR}_8$  or N; wherein  $\text{R}_8$  is chosen from hydrogen, hydroxy,  $\text{C}_{1-10}$ alkyl,  $\text{C}_{1-10}$ alkoxy, halo-substituted- $\text{C}_{1-10}$ alkyl and halo-substituted- $\text{C}_{1-10}$ alkoxy; or B is  $\text{CR}_9$  and E is carbon and B and E are connected via a double bond;

X is a bond or is chosen from  $-\text{X}_1\text{OX}_2-$ ,  $-\text{X}_1\text{NR}_7\text{X}_2-$ ,  $-\text{X}_1\text{C}(\text{O})\text{NR}_7\text{X}_2-$ ,  $-\text{X}_1\text{NR}_7\text{C}(\text{O})\text{X}_2-$ ,  $-\text{X}_1\text{S}(\text{O})\text{X}_2-$ ,  $-\text{X}_1\text{S}(\text{O})_2\text{X}_2-$ ,  $-\text{X}_1\text{SX}_2-$ ,  $\text{C}_{4-6}$ heteroarylene and  $-\text{X}_1\text{ON}=\text{C}(\text{R}_7)\text{X}_2-$ ; wherein  $\text{X}_1$  and  $\text{X}_2$  are independently chosen from a bond,  $\text{C}_{1-3}$ alkylene and  $\text{C}_{2-3}$ alkenylene;  $\text{R}_7$  is chosen from hydrogen and  $\text{C}_{1-6}$ alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and  $\text{C}_{1-6}$ alkyl;

Y is chosen from  $\text{C}_{6-10}$ aryl and  $\text{C}_{5-10}$ heteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydroxy, nitro,  $\text{C}_{1-10}$ alkyl,  $\text{C}_{1-10}$ alkoxy, halo-substituted  $\text{C}_{1-10}$ alkyl and halo-substituted  $\text{C}_{1-10}$ alkoxy; which process comprises:

(a) reacting a compound of formula 2:



with either *t*-butyl acrylate, acrylonitrile/ $\text{NaN}_3$  or bromoacetonitrile/ $\text{NaN}_3$ ; wherein B, E, Y, X,  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are as described above; and

(b) optionally converting a compound of the invention into a pharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention to a non-salt form;

(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form;

(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers;

(g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and

(h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.